Overview

A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the investigational drug CHR-2797 (given orally, once daily). The purpose of this study is to evaluate if it is safe to administer these two drugs together, and how well the combination is tolerated by patients. The first patients will receive a 90mg dose of CHR-2797; doses will be increased in subsequent patients, as long as they are adequately tolerated.

Phase:

Phase 1

Details

Lead Sponsor:

Chroma Therapeutics

Treatments:

Albumin-Bound Paclitaxel
Glycine
Paclitaxel
Tosedostat